Menu
Search
|

Menu

Close
X

Intellia Therapeutics Inc NTLA.OQ (NASDAQ Stock Exchange Global Market)

17.76 USD
+0.12 (+0.68%)
As of Jul 23
Previous Close 17.64
Open 17.67
Volume 143,353
3m Avg Volume 215,863
Today’s High 17.92
Today’s Low 17.52
52 Week High 32.95
52 Week Low 11.05
Shares Outstanding (mil) 45.71
Market Capitalization (mil) 806.34
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.92 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY19
10
FY18
30
FY17
26
FY16
16
EPS (USD)
FY19
-0.485
FY18
-1.984
FY17
-1.858
FY16
-1.075
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.39
Price to Sales (TTM)
vs sector
24.14
8.16
Price to Book (MRQ)
vs sector
3.03
4.43
Price to Cash Flow (TTM)
vs sector
--
24.27
Total Debt to Equity (MRQ)
vs sector
1.66
17.60
LT Debt to Equity (MRQ)
vs sector
0.00
12.56
Return on Investment (TTM)
vs sector
-26.89
12.67
Return on Equity (TTM)
vs sector
-30.70
17.18

EXECUTIVE LEADERSHIP

Perry Karsen
Independent Chairman of the Board, Since 2017
Salary: --
Bonus: --
John Leonard
President, Chief Executive Officer, Director, Since 2018
Salary: $550,000.00
Bonus: $302,500.00
Glenn Goddard
Chief Financial Officer, Since 2018
Salary: $67,718.00
Bonus: $51,652.00
Laura Sepp-Lorenzino
Executive Vice President, Chief Scientific Officer, Since 2019
Salary: --
Bonus: --
Jose Rivera
Executive Vice President, General Counsel, Since 2017
Salary: $417,200.00
Bonus: $166,880.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

40 Erie St Ste 130
CAMBRIDGE   MA   02139-4254

Phone: +1857.2856200

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.

SPONSORED STORIES